Order Article Reprints

Saez Perdomo MN, Stuckey R, González-Pérez E, Sánchez-Sosa S, Estupiñan-Cabrera P, Lakhwani Lakhwani S, González San Miguel JD, Hernanz Soler N, Gordillo M, González Brito G, et al. The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia. Hematology Reports. 2024; 16(1):140-150. https://doi.org/10.3390/hematolrep16010015

Saez Perdomo, María Nieves, Ruth Stuckey, Elena González-Pérez, Santiago Sánchez-Sosa, Paula Estupiñan-Cabrera, Sunil Lakhwani Lakhwani, José David González San Miguel, Nuria Hernanz Soler, Marina Gordillo, Gloria González Brito, and et al. 2024. "The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia" Hematology Reports 16, no. 1: 140-150. https://doi.org/10.3390/hematolrep16010015

Saez Perdomo, M. N., Stuckey, R., González-Pérez, E., Sánchez-Sosa, S., Estupiñan-Cabrera, P., Lakhwani Lakhwani, S., González San Miguel, J. D., Hernanz Soler, N., Gordillo, M., González Brito, G., Tapia-Torres, M., Ruano, A., Segura-Díaz, A., Luzardo, H., Bilbao-Sieyro, C., & Gómez-Casares, M. T. (2024). The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia. Hematology Reports, 16(1), 140-150. https://doi.org/10.3390/hematolrep16010015